Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY8 | P40145 | 11/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.51 |
| ▸ | ADCY1 | Q08828 | 14/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31590939 | 0.87 | SLC2A1 (0.47) | ADCY8SLC2A1ADCY1HTR2BKDM4E | |
| SCHEMBL31590694 | 0.87 | SLC2A1 (0.47) | ADCY8SLC2A1ADCY1HTR2BKDM4E | |
| SCHEMBL31590616 | 0.84 | SLC2A1 (0.47) | ADCY8SLC2A1ADCY1HTR2BKDM4E | |
| SCHEMBL31590680 | 0.83 | SLC2A1 (0.46) | ADCY8SLC2A1ADCY1HTR2BKDM4E | |
| SCHEMBL31590900 | 0.82 | KCNJ6 (0.62) | ADCY8SLC2A1ADCY1KDM4E | |
| SCHEMBL31591016 | 0.81 | KMT2A (0.58) | ADCY8SLC2A1ADCY1 | |
| SCHEMBL31591054 | 0.79 | SLC2A1 (0.45) | ADCY8SLC2A1ADCY1KDM4E | |
| SCHEMBL31590750 | 0.79 | MAPT (0.50) | ADCY8SLC2A1ADCY1HTR2BKDM4E | |
| SCHEMBL23249513 | 0.76 | SLC2A1 (0.67) | ADCY8SLC2A1ADCY1HTR2B | |
| SCHEMBL31590956 | 0.76 | SLC2A1 (0.43) | ADCY8SLC2A1ADCY1HTR2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040420-A | Heterocyclic-pyrazole amine derivatives, preparation method thereof and application thereof in resisting tubercle bacillus infection | 中国医学科学院医药生物技术研究所 | 2025-05-27 | — | — | CN | disclosed |